Login

Mert Karaoğlan

ORCID: 0000-0001-5069-685X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
A5018115391
Research Areas
  • Gastric Cancer Management and Outcomes
  • Peptidase Inhibition and Analysis
  • HER2/EGFR in Cancer Research

Ankara University
 2020-2021

 Trastuzumab ± Capecitabine Maintenance After the First-Line Treatment of HER2-Positive Advanced Gastric Cancer: Retrospective Observational Real-Life Data of Turkish Oncology Group
OPENALEX - Publications 
Mustafa Gürbüz Erman Akkuş Abdullah Sakin Semiha Urvay Atike Gökçen Demiray and 20 more Süleyman Şahin Teoman Şakalar Cihan Erol Mehmet Alı Nahıt Şendur Ahmet Bilgehan Şahin Erdem Çubukçu Deniz Can Güven Saadettin Kılıçkap Yakup Ergün Doğan Uncu N. S. Turhal Necdet Üskent Havva Yeşil Çınkır Atakan Demir Ramazan Acar Nuri Karadurmuş Sema Türker Mustafa Altınbaş Mert Karaoğlan Filiz Çay Şenler

10.1007/s12029-021-00594-1 article EN Journal of Gastrointestinal Cancer 2021-02-04
 Combination of trastuzumab and taxane-containing intensified chemotherapy in first-line treatment of HER2-positive advanced gastric cancer
OPENALEX - Publications 
Mustafa Gürbüz Erman Akkuş Abdullah Sakin Semiha Urvay Atike Gökçen Demiray and 20 more Süleyman Şahin Teoman Şakalar Cihan Erol Mehmet Alı Nahıt Şendur Ahmet Bilgehan Şahin Erdem Çubukçu Deniz Can Güven Saadettin Kılıçkap Yakup Ergün Doğan Uncu N. S. Turhal Necdet Üskent Havva Yeşil Çınkır Atakan Demir Ramazan Acar Nuri Karadurmuş Sema Türker Mustafa Altınbaş Mert Karaoğlan Filiz Çay Şenler

Taxane-containing combinations are recommended for the first-line therapy of advanced gastric cancer. It is not known which chemotherapy regimen best with trastuzumab HER2-positive patients. The aim this study was to compare taxane-containing intensified versus standard in combination treatment adenocarcinoma.This a retrospective multicenter Turkish Oncology Group. A total 130 patients inoperable locally advanced, recurrent, or metastatic adenocarcinoma being given plus as were included from...

10.1177/0300891620969823 article EN Tumori Journal 2020-11-09
Coming Soon ...